苏州厚朴惠康生物医药科技有限公司一直专注于细胞生物学领域，集基础研究、临床应用推广和产业化于一体的生物高科技企业。

厚朴惠康的核心技术是专能干细胞技术（间充质干细胞、神经干细胞、胰岛干细胞等）及全能型免疫细胞技术 (NK、ACTL、CAR-NK) 等，同时擁有创新疫苗研发平台、双特异性抗体联合细胞治疗临床技术平台与干细胞活性因子之护肤应用。尤其针对抗衰老研究、肿瘤预防与干预及慢病管理等临床药物开发应用已构建成熟技术平台。

厚朴惠康位于苏州，设有实验室皆按照欧盟标准 (A+B) 和中国新版 GMP 标准设计建造。

厚朴惠康目前共拥有55项专利，包括 18 项发明专利及 37 项实用型专利，并于 2020 年启动临床前研究申报新药程序以及备案免疫细胞临床技术。厚朴惠康並已形成以市场为导向，以产学研相结合的技术创新体系平台；在细胞抗衰老等相关技术运用在临床取得极佳成果，尤其体現在护肤方面的全新产品技术上。

Hopecell Biomedical Technology(Suzhou) Co., Ltd. is a biotech company dedicated to the field of cellular biotechnology, foundational research, clinical applications, and commercialization.

Hope Group’score technology is the translational development of stem cell technology (mesenchymal stem cells, neural stem cells, and pancreatic stem cells). In addition, Hope Group possess proprietary immune cell therapy platform (NK, ACTL, CAR-NK, etc.) and has the capabilities in innovative vaccine research, bi-specific antibody BsAb with immune cell therapy technology, and stem cell derived skin care applications. Hope Group has cultivated and established a mature technological platform for clinical drug development in areas of anti-aging research, tumor prevention and intervention, and chronic disease management in China.

Hope Group is headquartered in Suzhou, a major city in China’s Jiangsu Province. Its facility includes laboratory space designed and constructed in accordance with European Union standards (A+B) and China’s new GMP standards.

Hope Group currently holds 55 patents, including 18 invention patents and 37 utility patents. In 2020, Hope Group commenced pre-clinical research for new drug application process and filing for clinical immune cell technology. Hope Group has a market-oriented technology innovation platform that combines production, training, and research. Hope Group achieves good clinical results in cellular anti-aging applications and other related technologies, especially in new skin care products.